Overview

A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides

Status:
Completed

Trial end date:
2011-08-23

Target enrollment:

Participant gender:

Summary

This Phase 2 proof-of-concept study will assess the lipid regulating efficacy and safety of ETC-1002 in subjects with hypercholesterolemia and either normal or elevated triglycerides.

Phase:

Phase 2

Details

Lead Sponsor:

Esperion Therapeutics
Esperion Therapeutics, Inc.

Treatments:

8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid